Company news

CG Oncology, Inc. news in 2024

CG Oncology, Inc.'s news releases, calls and decks from 2024, newest first.

View company

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 15, 2024

CG Oncology Announces Pricing of Public Offering

December 11, 2024

CG Oncology Announces Proposed Public Offering

December 10, 2024

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

December 5, 2024

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

December 4, 2024

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

December 1, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

November 19, 2024

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 11, 2024

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

November 10, 2024

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 29, 2024

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 7, 2024

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

June 17, 2024

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

June 5, 2024

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 23, 2024

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 2, 2024

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

April 25, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

April 23, 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

March 27, 2024

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

February 26, 2024

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 29, 2024

CG Oncology Announces Pricing of Upsized Initial Public Offering

January 23, 2024

Decks in 2024